TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Aktis Oncology, a clinical-stage oncology company focused on targeted radiopharmaceuticals, priced its IPO at $18 per share, raising approximately $318 million. The company's stock is set to begin trading on Nasdaq under ticker 'AKTS' on January 9, 2026, with the offering expected to close on January 12, 2026.

Insights
NVDA   positive

Listed as a key player in AI medical device technologies


LLY   neutral

Eli Lilly is mentioned as having a strategic collaboration with Aktis to develop novel radioconjugates. While this represents a partnership opportunity, the article provides no details about the scope, financial terms, or strategic significance of the collaboration, warranting a neutral sentiment.